ライフサイエンスコーパス: recombinant virus

1 se genetics, we generated a ToV-PLP knockout recombinant virus.

2 nor effect on the virulence of the resulting recombinant virus.

3 d as well as wild-type L in the context of a recombinant virus.

4 s reactivated the WT parent but not the R111 recombinant virus.

5 epidemic from another swine influenza A H1N1 recombinant virus.

6 G15 antagonist function and yielded a viable recombinant virus.

7 ) are limited by inefficient recovery of the recombinant virus.

8 to the phenotype observed for the UL138-null recombinant virus.

9 a molecular clone, and recovered a wild-type recombinant virus.

10 This holds when H3 or H5 replaces H1 in recombinant viruses.

11 priming in mouse CMV (MCMV) infection using recombinant viruses.

12 d or clonal envelopes were used to construct recombinant viruses.

13 ation in mice was analyzed using a series of recombinant viruses.

14 ination with transcomplementation assays and recombinant viruses.

15 ored polypeptide synthesis from plasmids and recombinant viruses.

16 two HA mutations were analyzed by generating recombinant viruses.

17 sion, we have successfully constructed three recombinant viruses.

18 global viral gene expression between WT and recombinant viruses.

19 ackground to construct replication-competent recombinant viruses.

20 ed A774wt) were used to construct a panel of recombinant viruses.

21 ed fusion activity and engineered these into recombinant viruses.

22 Passage of one recombinant virus, A117F, identified a second site suppr

23 itro and virulence in vivo, we show that the recombinant viruses accurately recapitulate the replicat

24 These recombinant viruses allowed the identification of the re

25 This recombinant virus also provided protection against letha

26 Here we report an HTLV-1 recombinant virus among infected individuals in North Af

27 such an event affects the host range of the recombinant virus and can lead to the creation of novel

28 re-derived an infectious full-length SHC014 recombinant virus and demonstrate robust viral replicati

29 this is a sacrifice for the virus, we used a recombinant virus and transfected cells expressing const

30 and their epitopes were finely mapped using recombinant viruses and alanine scan mutation array tech

31 We also generated recombinant viruses and analyzed their infections in cel

32 e determinants of the host range, infectious recombinant viruses and chimeras of a genotype 1 isolate

33 eraction was detected on virions produced by recombinant viruses and correlated with reduced target c

34 Combining fluorescent protein expressing recombinant viruses and multimodal, macroscopic and micr

35 mmune responses by using cytokine-expressing recombinant viruses and that neonatal deficiency in IFN-

36 lasmids, which can be used for the rescue of recombinant viruses and/or the creation of vaccine seed

37 rmed the associated molecular changes in the recombinant viruses, and sequence analysis demonstrated

38 n the OTU domain region generated the viable recombinant viruses, and the S462A and D465A mutants wer

39 We propose that these recombinant viruses are convenient and valuable tools fo

40 Recombinant viruses are genetically stable and induce po

41 Recombinant virus ASFV-G-DeltaMGF effectively confers pr

42 Here we report the construction of a recombinant virus (ASFV-G-DeltaMGF) derived from the hig

43 t the construction of a double-gene-deletion recombinant virus, ASFV-G-Delta9GL/DeltaUK.

44 sequences of K3 or K5 into a DeltaK3 DeltaK5 recombinant virus, at either original or interchanged ge

45 aluation of Gag function in the context of a recombinant virus backbone.

46 idation of an algorithm capable of detecting recombinant viruses based on diagnostic microarray hybri

47 Infection of aged, but not young, mice with recombinant viruses bearing spike glycoproteins derived

48 In vivo, MuHV-4 recombinant viruses bearing these mLANA SOCS box mutatio

49 s-based reverse genetics system to produce a recombinant virus, Bristol tsc31 (MHV-Brtsc31), which ha

50 y retained the attenuation properties of the recombinant virus but enhanced the expression level of H

51 nd BJAB cells with wild-type and the K8-null recombinant viruses by introducing the cloned viral geno

52 lization approach in which we fed virions or recombinant virus capsid components to whiteflies, follo

53 We showed previously that a recombinant virus carrying a deletion of the carboxyl-te

54 Studies with recombinant viruses carrying mutations in this region co

55 Recombinant viruses carrying YNND mutations in AD-5 were

56 Immunization of mice with this recombinant virus conferred complete protection from let

57 Vaccination of chickens with these recombinant viruses conferred complete protection agains

58 f specific-pathogen-free chickens with these recombinant viruses conferred significant protection aga

59 and neurovirulence by generating a series of recombinant viruses consisting of combinations of genes

60 Recombinant virus containing a mutation at the T286 posi

61 The recombinant virus containing all three mutations, gDDelt

62 We generated HTLV-1 envelope recombinant virus containing the HTLV-2 SU domain.

63 A recombinant virus containing the P-T101A mutation (rMuV-

64 T lacks ATP-dependent excision activity, and recombinant virus containing this RT remains susceptible

65 f wild-type and laboratory-adapted MVs using recombinant viruses containing an additional transcripti

66 on antigenicity, we constructed a series of recombinant viruses containing different mutation combin

67 and T212I, were characterized by generating recombinant viruses containing either one or both amino

68 Recombinant viruses containing full-length plasma-derive

69 Here we analyzed recombinant viruses containing HA with exchange of conse

70 if these mutations affect virus replication, recombinant viruses containing single-amino-acid substit

71 Recombinant viruses containing these mutations were then

72 The recombinant virus DC474-480 constructed with tyrosines 4

73 the role of UL37 in virion envelopment, the recombinant virus DC480 was constructed by insertion of

74 rfaces was enhanced in cells infected with a recombinant virus defective in 14-3-3 binding.

75 al or greater protection than rXlIFN against recombinant viruses deficient for the putative immune ev

76 Infection of A549 cells with recombinant viruses deficient in the expression of NS1 a

77 The recombinant virus DeltagM2, engineered not to express gM

78 The recombinant virus DeltaUL11-DeltagM2, engineered not to

79 We constructed a recombinant virus (DeltaXX) that lacks amino acids 87 to

80 could not allow for the generation of viable recombinant viruses, demonstrating that these residues a

81 Using a recombinant virus derived from the JFH1 strain, we confi

82 Using reverse genetics, we generated a recombinant virus, designated r2segMP12, containing a tw

83 ence of MHV-A59, and mice infected with this recombinant virus developed pulmonary lesions that were

84 This recombinant virus, E1DeltaCys24/94v, showed delayed grow

85 For this study, we constructed an HCMV recombinant virus encoding a carboxy-terminal domain tru

86 Here using a recombinant virus encoding a NS1B protein defective in I

87 A recombinant virus encoding an M protein with seven lysin

88 P13/14 from lysates of cells infected with a recombinant virus encoding His-tagged pU(L)17.

89 Recombinant virus encoding the NSs core domain induced i

90 Recombinant viruses encoding amino acid changes in the H

91 Recombinant viruses encoding M2 proteins with a serine s

92 Recombinant viruses encoding M2 with the Y76A mutation d

93 irus-based reverse genetic system to produce recombinant viruses encoding ns2 proteins with single-am

94 nsmission, the replication capacities of 148 recombinant viruses encoding plasma-derived Gag-protease

95 ess, we utilized reverse genetics to produce recombinant viruses encoding wild-type M1 41P (rSPN04-P)

96 These recombinant viruses expressed two additional copies of t

97 ng viral DNA in infected cells, we created a recombinant virus expressing a FLAG-tagged version of UL

98 -specific CD8(+) T cells or vaccination with recombinant virus expressing an MHC I-restricted Chlamyd

99 A recombinant virus expressing E1086A D1087A mutant ICP8 w

100 Furthermore, a recombinant virus expressing H7N9 NS1-I106M replicates t

101 Recombinant virus expressing pHA-UL3825-331 replicated w

102 by tandem-affinity purification (TAP) using recombinant viruses expressing either a full-length NTAP

103 ns in modulating DC maturation by generating recombinant viruses expressing enhanced green fluorescen

104 We generated recombinant viruses expressing G and F, or null for G, f

105 icating adenovirus type 5 host range (Ad5hr) recombinant viruses expressing human immunodeficiency vi

106 ection with IL-12p35 or IL-12p40 DNA or with recombinant viruses expressing IL-12p35 or IL-12p40.

107 changes in the optic nerve and CNS, whereas recombinant viruses expressing IL-4, gamma interferon, I

108 ty of a MERS-CoV molecular clone, as well as recombinant viruses expressing indicator proteins, will

109 Here, we used recombinant viruses expressing mutant NS1 from the A/Tex

110 Moreover, recombinant viruses expressing O3 homologs in place of O

111 Recombinant viruses expressing subtype C Gag-proteases e

112 nfected with mouse cytomegalovirus (MCMV) or recombinant viruses expressing the viral m157 glycoprote

113 Both B5 and B5-GFP recombinant viruses expressing these mutant proteins in

114 e also observed by utilizing three different recombinant viruses expressing unique fluorescent report

115 Using a recombinant virus-expression system in tissue culture an

116 A recombinant virus, FIX-UL138(STOP), that synthesizes the

117 lar clones, as well as for the generation of recombinant virus from the molecular clones.

118 We then generated recombinant viruses from cloned cDNAs prepared to the an

119 ved with a previously described panel of six recombinant viruses from five different subtypes.

120 In contrast, recombinant viruses from which the VNDT motif is deleted

121 n D (gD) in the presence or absence of gE, a recombinant virus (gDDeltact) was constructed to specify

122 The recombinant virus gDDeltaTEV was engineered to eliminate

123 Deletion of the E2RE in the context of a recombinant virus greatly diminished levels of Cp-initia

124 It was found that all the recombinant viruses grew as well as the parent virus, an

125 Interestingly, one of the recombinant viruses had a 34-amino-acid duplication at t

126 These recombinant viruses had a significant decrease in both g

127 n was nearly absent in cells infected with a recombinant virus harboring an S369A mutation within the

128 We found that a recombinant virus harboring the duplication bound more e

129 use model utilizing Cre recombinase-encoding recombinant viruses harboring deletions of the core LAT

130 Recombinant viruses harboring engineered deletions of sp

131 Here we observed that recombinant viruses harboring individual cysteine-to-ser

132 tein to inhibit general gene expression, and recombinant viruses harboring these mutations were atten

133 Recombinant viruses have pros and cons as vaccine carrie

134 Recombinant viruses having either tyrosine 476 or 477 re

135 Recombinant viruses hold promise as vectors for vaccines

136 l lines demonstrated that replication of the recombinant virus, HSV-GS3, is strictly dependent on an

137 After infection with this recombinant virus, IL-4 secretion was enhanced.

138 n cells was altered after infection with the recombinant virus in comparison to the levels with the p

139 Taking advantage of a recombinant virus in which F18 expression is IPTG (isopr

140 ction, the BAC system was used to generate a recombinant virus in which the UL55 gene was replaced wi

141 Passage of the recombinant viruses in cell culture led to the accumulat

142 We generated a panel of US28 recombinant viruses in the bacterial artificial chromoso

143 fectivity, and growth kinetics of these four recombinant viruses in vitro.

144 e genetics, we developed a method to recover recombinant viruses in which independent selection strat

145 and extend the siRNA results, we constructed recombinant viruses in which pUL48 and pUL103 are fused

146 A pair of chimeric recombinant viruses in which the nucleocapsid gene was e

147 Entry and spread profiles of the recombinant viruses indicated that gD retargeting does n

148 AC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific

149 rmine whether the ocular infection with this recombinant virus induces optic neuritis independent of

150 to the same extent as the parental wild-type recombinant virus, inf-MHV-A59.

151 Expression of ILTV gB and gD proteins in the recombinant virus-infected cells was detected by immunof

152 hese results suggest that the rLS/AMPV-C F&G recombinant virus is a safe and effective bivalent vacci

153 The recombinant virus is virulent in established ZIKV mouse

154 The replication of these recombinant viruses is attenuated, and they have an enha

155 th pathogen-associated molecular patterns or recombinant viruses is being tested in the clinic.

156 clones and demonstrate that the behavior of recombinant viruses is similar to that of the wild type.

157 By using an engineered recombinant virus, it was further determined that althou

158 Additionally, cells infected with the recombinant viruses KSHVDeltaK1 and KSHV-K15xSTOP also y

159 We report that the recombinant viruses KSHVDeltaK1 and KSHV-K15xSTOP displa

160 Using a recombinant virus lacking PB1-F2, we confirmed that dele

161 Using a recombinant virus lacking the BBD, we examined pathogene

162 Infection of mice with recombinant viruses lacking M33 or containing specific s

163 vel expression of hNIS is detrimental to the recombinant virus, leading to the aggregation of hNIS pr

164 Infection of C57BL/6 mice with this recombinant virus led, however, to the generation of abu

165 and four distinct Fabs reactive with Norwalk recombinant virus-like particles (rVLPs) were recovered,

166 persistence, we built structural models and recombinant virus-like particles (VLPs) of five GI strai

167 did not affect the HBGA binding profiles of recombinant virus-like particles derived from representa

168 ction of 25 different norovirus genotypes as recombinant virus-like particles or in clinical samples

169 The structure of recombinant virus-like particles, composed of 60 copies

170 se chimeras are viable and suggest that such recombinant viruses may be useful for investigation of d

171 Together these data suggest this recombinant virus merits further study for its oncolytic

172 Infant-derived Gag-protease NL4-3 recombinant viruses (n = 41) were found to have a signif

173 x 2 domain (V2566A, G2567A, I2568A) produced recombinant virus NS4B.VGIv, with an altered phenotype d

174 irected mutagenesis, we found that a 1918 HA recombinant virus, of high virulence, could be significa

175 We generated two recombinant viruses, one in which the nonstructural prot

176 ferrets with beta-propiolactone-inactivated recombinant virus particles elicited protective RABV ant

177 These chimeric recombinant viruses possess growth properties similar to

178 ing a reverse genetics approach by comparing recombinant viruses possessing amino acid substitutions

179 Recombinant viruses predominantly expressing GP1,2 are k

180 and extracellular viruses revealed that all recombinant viruses produced viral titers similar to tho

181 ed components of the viral polymerase, while recombinant viruses propagated in MDBK cells acquired mu

182 Recombinant viruses propagated in Vero cells acquired mu

183 tro and in vivo, and immunization with these recombinant viruses protected mice against lethal influe

184 The recombinant virus R112 carrying the dnREST replicated be

185 the establishment of latency, we constructed recombinant virus (R112) carrying a dominant-negative RE

186 Recombinant virus (rAAV) leptin antagonism in the VTA de

187 The rescued recombinant virus (rAPMV-2) resembled the biological vir

188 onasal or intramuscular challenge, all three recombinant viruses (rAPMV3, rAPMV3-F, and rAPMV3-HN) we

189 Two recombinant viruses, rAPMV3-F and rAPMV3-HN, were genera

190 A recombinant virus, rBUNdelNSs, that is unable to express

191 e; after two rounds of selective passage the recombinant virus reaches titers of >/=10(4) pfu/mL.

192 methods for RV may enhance the efficiency of recombinant virus recovery.

193 Yet the recombinant virus remained completely defective for prod

194 ich otherwise lacks the locus, the resulting recombinant virus replicated similarly to the parental v

195 The recombinant viruses replicated efficiently in both HEp-2

196 Recombinant viruses replicated in an ORF30-complementing

197 The recombinant viruses replicated to near-wild-type titers,

198 The H5N1 PB1-V43I-recombinant virus replicates to comparable titres as the

199 Insertion of the TC tag interfered with recombinant virus rescue in six of the eight mutants, li

200 mination of the N mRNA and were required for recombinant virus rescue.

201 ombinants, corneal route inoculation by R112 recombinant virus resulted in higher DNA copy numbers, h

202 on of Nicotiana benthamiana plants with such recombinant virus resulted in production of huge amounts

203 use bone marrow-derived DCs with each of the recombinant viruses resulted in DC activation, as shown

204 infection of cynomolgus macaques with these recombinant viruses revealed differences in immunogenici

205 Here, we subjected a recombinant virus (rH1N1) with the same constellation ma

206 Cs that were elicited by the IL-7-expressing recombinant virus (rLBNSE-IL-7) were able to sustain VNA

207 The recombinant virus, rLS/AMPV-C F&G, was slightly attenuat

208 These recombinant viruses, rLS/ILTV-gB and rLS/ILTV-gD, were s

209 ed full-length transcripts recovered several recombinant viruses (rMERS-CoV) that contained the expec

210 We have constructed a RRV recombinant virus (RRVDeltaLANA/GFP) in which the RRV LA

211 The resultant recombinant viruses (rVSV-HSP70-VP1 and rVSV-Luc-VP1) we

212 These results indicate that attenuated recombinant viruses show reduced neurovirulence and that

213 The recombinant virus showed distinct changes in tissue trop

214 oculated intranasally with any of these live recombinant viruses showed no signs of disease, includin

215 To investigate its role, we created the recombinant virus SMin79, in which pM79 expression was d

216 vestigate the role of pM92, we constructed a recombinant virus SMin92, in which pM92 expression was d

217 Results of genetic studies using recombinant virus strains show that reovirus tropism for

218 ding of both virus-like particles (VLPs) and recombinant viruses, suggesting that 14-3-3 binding impa

219 ron function.IMPORTANCE We developed a novel recombinant virus that allows the study of cells that su

220 the PIV5 wild type (wt) and PIV5-VDeltaC (a recombinant virus that does not encode a functional V pr

221 A recombinant virus that fails to express both pUL133 and

222 is a novel herpes simplex virus (HSV) type 1 recombinant virus that is completely replication-defecti

223 Therefore, we generated a recombinant virus that is no longer able to express sGP

224 The recombinant viruses that arise in nature are occasionall

225 Using reverse genetics, we generated recombinant viruses that contained deletions within the

226 the KSHV life cycle, we constructed a set of recombinant viruses that contained either wild-type (WT)

227 in infection, we generated a series of ZIKV recombinant viruses that disrupted the hydrogen-bonding

228 Further, using recombinant viruses that establish a nonreactivating, la

229 We generated recombinant viruses that express a consensus BA G gene o

230 nfluence reovirus entry events, we generated recombinant viruses that express chimeric T1L-T3D mu1 pr

231 ion assay to determine the entry kinetics of recombinant viruses that incorporated full-length VCV-se

232 ibition of viral RNA synthesis by generating recombinant viruses that lack known ISGylation sites in

233 Utilizing recombinant viruses that mutate the miRNA-binding site c

234 in in the life cycle of KSHV, we constructed recombinant viruses that were deficient for K1.

235 ed to the production of genetically modified recombinant viruses that, while attenuated, are able to

236 en these mutations were engineered back into recombinant viruses, the resulting viruses replicated we

237 VSVDeltaG vector restored the ability of the recombinant virus to replicate in cell culture, without

238 vention of the alternate splice returned the recombinant virus to the wild-type phenotype.

239 The ability of these recombinant viruses to activate DCs was determined in vi

240 e candidate mutations were incorporated into recombinant viruses to determine their in vivo effect.

241 The recombinant virus, UL12 D340E (the D340E mutant), behave

242 We show here that this recombinant virus vaccine candidate was nonpathogenic in

243 iate, but by using the direct infection of a recombinant virus vector based on the plant virus, tobac

244 A recombinant virus, vNC-Venus-ICP27, was constructed, and

245 Three recombinant viruses, vR128A, vR129A, and vRR129AA, carry

246 bit NF-kappaB activation but that the viable recombinant viruses, vSD-S462A and vSD-D465A, were unabl

247 The recombinant virus was assembly deficient, as judged by t

248 The integrity of the recombinant virus was confirmed by diagnostic PCR, restr

249 The VC2-EHV-1-gD recombinant virus was constructed by inserting an EHV-1

250 The 1918 HA recombinant virus was further attenuated by introducing

251 15 production and conjugation, but no viable recombinant virus was recovered.

252 This recombinant virus was unable to establish latency.

253 Using recombinant virus, we demonstrate for the first time PVM

254 Using these recombinant viruses, we assessed the requirement for US2

255 Using recombinant viruses, we demonstrate that while Cp is not

256 mammalian protein complementation assay and recombinant viruses, we found that an increase in P(XD)-

257 Using recombinant viruses, we identify the HA genomic segment

258 periments revealed that A774wt and avirulent recombinant virus were characterized by increased proces

259 All recombinant viruses were attenuated both in vitro and in

260 Recombinant viruses were constructed to abolish either g

261 Recombinant viruses were generated that contained either

262 Three recombinant viruses were generated that contained the op

263 In addition, these recombinant viruses were highly attenuated in cell cultu

264 the replication capacities of the resulting recombinant viruses were measured in an HIV-1-inducible

265 hment protein- and fusion protein-expressing recombinant viruses were protected from lethal CDV chall

266 Recombinant viruses were reconstituted by introduction o

267 These recombinant viruses were safe, stable, and immunogenic a

268 These recombinant viruses were specifically defective in ribos

269 These recombinant viruses were specifically defective in ribos

270 into the wild-type HSV-1(F) genome, and the recombinant viruses were tested for raltegravir resistan

271 ulent than the wild-type parent or the other recombinant viruses when administered by the corneal or

272 plasticity of the BUNV genome by generating recombinant viruses where the normal negative-sense S se

273 Another recombinant virus, which induced a slowly developing "in

274 ed influenza virus vaccines (LAIVs) based on recombinant viruses whose genomes encode nonoverlapping

275 a bacterial artificial chromosome (BAC) KSHV recombinant virus with a deletion of the RBP-Jkappa site

276 HAdV-C57 is a recombinant virus with a fiber gene nearly identical to

277 wild-type V protein (rBC), (ii) an isogenic recombinant virus with a mutant V protein (rBC-Edit viru

278 Recombinant virus with a nonphosphorylatable alanine (Al

279 e pathogenicity of the virus, we generated a recombinant virus with a single amino acid mutation at t

280 -type RRV(17577) (WT(BAC) RRV) to generate a recombinant virus with all 8 of the vIRFs deleted (vIRF-

281 In our study, a recombinant virus with seven gene segments from a human

282 uses with reduced inhibition by oseltamivir (recombinant virus with the E119A mutation generated by r

283 Recombinant virus with the PA M285K mutation completely

284 A recombinant virus with these two segments replicated mor

285 protein, we compared the properties of four recombinant viruses with altered HA protein acid stabili

286 Recombinant viruses with altered NP proteins were genera

287 vitro assays of viral protein functions and recombinant viruses with defined genetic modifications h

288 Newcastle disease virus (NDV), we generated recombinant viruses with deletions in 5' and 3' UTRs of

289 e function of pUL33, we generated a panel of recombinant viruses with either deletions or substitutio

290 the UL25 capsid binding domain, we generated recombinant viruses with either small truncations or ami

291 mivir, zanamivir, and peramivir by assessing recombinant viruses with mutant NA-encoding genes (catal

292 Recombinant viruses with only the fusion protein in thei

293 ation and viral pathogenesis, we constructed recombinant viruses with or without mutations within the

294 9 virus promoted aerosol transmissibility to recombinant viruses with PR8 and sw/Tx/98 virus backgrou

295 In addition, we isolated recombinant viruses with specific alanine substitutions

296 Recombinant viruses with the third-wave NS gene induced

297 Recombinant viruses with these substitutions were genera

298 New alternative strategies for generating recombinant viruses with vaccine potential are needed.

299 hese residues were mutated to alanine, and a recombinant virus, WRL-A, was constructed.

300 In this study, we rescued recombinant virus WSN-AichiM1 containing the spherical A